Immunology and Cell Biology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 13, 2024

Abstract Natural killer (NK) cells play a vital role in innate immunity and show great promise cancer immunotherapy. Traditional sources of NK cells, such as the peripheral blood, are limited by availability donor variability. In addition, vitro expansion can lead to functional exhaustion gene editing challenges. This study aimed harness induced pluripotent stem cell (iPSC) technology provide consistent scalable source overcoming limitations traditional enhancing potential for immunotherapy applications. We developed human placental–derived iPSC lines using reprogramming techniques. Subsequently, an optimized two‐step differentiation protocol was introduced generate high‐purity cells. Initially, iPSCs were differentiated into hematopoietic‐like spin‐free embryoid bodies (EBs). EBs transferred ultra‐low attachment plates induce differentiation. iPSC‐derived (iNK) expressed common markers (NKp46, NKp30, NKp44, CD16 eomesodermin) at both RNA protein levels. iNK demonstrated significant resilience cryopreservation exhibited enhanced cytotoxicity. The incorporation chimeric antigen receptor (CAR) construct further augmented their cytotoxic potential. exemplifies feasibility generating with high purity capabilities, improved have cytotoxicity through CAR expression. Our findings offer promising pathway development cellular immunotherapies, highlighting critical challenges associated sources.

Language: Английский